No Data
Shenzhen Salubris Pharmaceuticals (002294.SZ): Some small nucleic acid projects will be in preclinical research next year.
Gelonghui reported on December 13 that Shenzhen Salubris Pharmaceuticals (002294.SZ) recently stated in an investor relations activity that some small nucleic acid projects are in preclinical research, and further R&D progress will be announced in due course.
Shenzhen Salubris Pharmaceuticals (002294.SZ): It is expected that 1 to 2 new products will be launched each year in the future.
On December 13th, Gelonghui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ) stated in a recent investor relations activity that the company is deeply engaged in the chronic disease field, focusing on cardiovascular and cerebrovascular areas, while expanding into nephrology, orthopedics, metabolism, and autoimmune fields. The company currently has 4 newly launched drugs, primarily for hypertension, nephrology, and diabetes, and it is expected that 1-2 new products will be launched each year in the future. With the aging population, the demand in these areas will also be tremendous, and the company's products have distinguishing features, leading to a good outlook.
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Price Is Out Of Tune With Earnings
Shenzhen Salubris Pharmaceuticals' Two Drugs Added to National Medical Insurance Catalog
Shenzhen Salubris Pharmaceuticals (002294.SZ): Alisartan, amlodipine besylate tablets and benzylidene-foglin tablets have been newly added to the national medical insurance catalog.
Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that according to the announcement released by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security...
Shenzhen Salubris Pharmaceuticals (002294.SZ): Plans to increase capital by 30 million yuan to Pure Benchmark.
Gelonghui November 22nd | Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that, according to the company's global strategy development plan, Shenzhen Salubris Pharmaceuticals Co., Ltd. plans to increase its stake in the company Peking Symbol Technology (Beijing) Co., Ltd. referred to as 'Peking Symbol' or 'the target company') with self-raised funds of RMB 30 million, and obtain 3.2154% equity of Peking Symbol. After this capital increase is completed, the company will directly hold 8.5745% equity of Peking Symbol. Prior to the capital increase, the company and its subsidiary controlling enterprise Ningbo Meishan Bonded Port Zone Wo Sheng Jingjia Equity Investment Partnership Enterprise (Limited Partnership) (referred to as 'Wo Sheng Jingjia'),
No Data
